{"organizations": [], "uuid": "db9faff4ae9e1347d205e9d714228948fc1b1846", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-juniper-pharmaceuticals-outlines-s/brief-juniper-pharmaceuticals-outlines-strategic-priorities-for-2018-and-reports-recent-portfolio-progress-idUSFWN1OX0NS", "country": "US", "domain_rank": 408, "title": "BRIEF-Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-02T23:10:00.000+02:00", "replies_count": 0, "uuid": "db9faff4ae9e1347d205e9d714228948fc1b1846"}, "author": "", "url": "https://www.reuters.com/article/brief-juniper-pharmaceuticals-outlines-s/brief-juniper-pharmaceuticals-outlines-strategic-priorities-for-2018-and-reports-recent-portfolio-progress-idUSFWN1OX0NS", "ord_in_thread": 0, "title": "BRIEF-Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-juniper pharmaceuticals outlines strategic priorities", "sentiment": "negative"}, {"name": "merck kgaa", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "juniper pharmaceuticals inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 11 PM / Updated 7 minutes ago BRIEF-Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress Reuters Staff \nJan 2 (Reuters) - Juniper Pharmaceuticals Inc: \n* JUNIPER PHARMACEUTICALS OUTLINES STRATEGIC PRIORITIES FOR 2018 AND REPORTS RECENT PORTFOLIO PROGRESS \n* JUNIPER PHARMACEUTICALS INC - ON TRACK TO BE CASH FLOW POSITIVE IN 2018 \n* JUNIPER PHARMACEUTICALS INC - CONTINUED “STRONG” DOUBLE-DIGIT REVENUE GROWTH FOR CRINONE AND JPS EXPECTED IN 2018 \n* JUNIPER - ACTIVE DISCUSSIONS WITH MERCK KGAA TO EXTEND CRINONE PROGESTERONE GEL AGREEMENT ARE PROGRESSING \n* JUNIPER PHARMACEUTICALS INC - PARTNERING OPPORTUNITIES ARE BEING “EXPLORED” FOR JNP-0101, THE OXYBUTYNIN IVR FOR TREATMENT OF OVERACTIVE BLADDER \n* JUNIPER PHARMACEUTICALS - PARTNERING OPPORTUNITIES ARE BEING “EXPLORED” FOR JNP-0301, A NATURAL PROGESTERONE IVR FOR PREVENTION OF PRE-TERM BIRTH Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-02T23:10:00.000+02:00", "crawled": "2018-01-02T23:25:12.000+02:00", "highlightTitle": ""}